Skip to main content

Table 3 Effects of zafirlukast in subjects maintained on ics

From: Tolerance and rebound with zafirlukast in patients with persistent asthma

  ICS-treated + Placebo Change from baseline ICS-treated + Zafirlukast Change from baseline
  Baseline (N = 8) Weeks 0–5 (N = 8) Weeks 6–10 (N = 8) Week 11–12 (N = 8) *W/D (N = 8) Baseline (N = 15) Weeks 0–5 (N = 15) Weeks 6–10 (N = 13) Week 11–12 (N = 13) *W/D (N = 11)
PEFR a.m., L/min 353 (± 32.3) +13.9 (± 6.1) +21.1 (± 9.6) +17.5 (± 12.2) +10.4 (± 6.6) 389 (± 21.2) +15.7 (± 5.0) +16.7 (± 6.1) +2.7 (± 15.2) -7.4 (± 6.3)
PEFR p.m., L/min 373 (± 32.8) +9.4 (± 10.0) +6.4 (± 15.0) +17.7 (± 12.1) +5.3 (± 6.2) 404 (± 20.0) +10.5 (± 4.9) +10.9 (± 5.8) -0.6 (± 15.0) -23.1 (± 6.6)
FEV1, mL 2,567 (± 225) -134 (± 67.7) -130 (± 47.2) -23.8 (± 93.6) +78.8 (± 59.6) 2,540 (± 179) +105 (± 72.5) -39.2 (± 74.7) +144 (± 106) -94.5 (± 48.0)
β2-agonist use per day 3.9 (± 0.6) -0.8 (± 0.47) -1.2 (± 0.68) -0.3 (± 1.0) -0.4 (± 0.4) 3.7 (± 0.5) -0.8 (± 0.25) -0.9 (± 0.32) -1.1 (± 0.4) +0.6 (± 0.47)
Severity score 2.0 (± 0.02) -0.3 (± 0.1) -0.3 (± 0.1) -0.03 (± 0.04) -0.1 (± 0.1) 1.8 (± 0.7) -0.3 (± 0.1) -0.3 (± 0.1) -0.4 (± 0.2) +0.1 (± 0.2)
**Total mornings 5.7 (± 0.8) -1.8 (± 0.8) -3.2 (± 0.9) -2.3 (± 1.4) -0.8 (± 2.2) 3.2 (± 0.6) -0.7 (± 0.4) -1.1 (± 0.7) -0.6 (± 0.5) +0.4 (± 0.3)
**Total awakenings 1.5 (± 0.9) -0.8 (± 0.7) -0.8 (± 0.5) -1.1 (± 0.7) +0.4 (± 1.1) 1.8 (± 0.7) -0.6 (± 0.5) -0.9 (± 0.6) -1.6 (± 0.7) +1.4 (± 1.0)